{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:42:44Z","timestamp":1786120964808,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim International GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ard.2026.07.005","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T03:31:03Z","timestamp":1785468663000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Circulating biomarkers in patients with systemic sclerosis\u2013associated interstitial lung disease in the SENSCIS trial"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8059-9978","authenticated-orcid":false,"given":"Shervin","family":"Assassi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Kuwana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P","family":"Denton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby M","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Diefenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Ittrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ard.2026.07.005_bib0001","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ard.2026.07.005_bib0002","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1164\/rccm.201903-0486OC","article-title":"Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort","volume":"200","author":"Hoffmann-Vold","year":"2019","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.ard.2026.07.005_bib0003","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/annrheumdis-2020-217455","article-title":"Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database","volume":"80","author":"Hoffmann-Vold","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.ard.2026.07.005_bib0004","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00161-2019","article-title":"Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases","volume":"54","author":"Wollin","year":"2019","journal-title":"Eur Respir J."},{"issue":"2 Suppl","key":"10.1016\/j.ard.2026.07.005_bib0005","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/2397198320903867","article-title":"Pathogenesis of systemic sclerosis associated interstitial lung disease","volume":"5","author":"Nihtyanova","year":"2020","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.ard.2026.07.005_bib0006","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ard.2026.07.005_bib0007","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004240","article-title":"Development of a multivariable prediction model for progression of systemic sclerosis-associated interstitial lung disease","volume":"10","author":"Kuwana","year":"2024","journal-title":"RMD Open."},{"key":"10.1016\/j.ard.2026.07.005_bib0008","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Series B Stat Methodol."},{"key":"10.1016\/j.ard.2026.07.005_bib0009","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2796.2006.01704.x","article-title":"Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases","volume":"260","author":"Satoh","year":"2006","journal-title":"J Intern Med."},{"key":"10.1016\/j.ard.2026.07.005_bib0010","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.3899\/jrheum.160339","article-title":"Elevated serum Krebs von den Lungen-6 in early disease predicts subsequent deterioration of pulmonary function in patients with systemic sclerosis and interstitial lung disease","volume":"43","author":"Kuwana","year":"2016","journal-title":"J Rheumatol."},{"key":"10.1016\/j.ard.2026.07.005_bib0011","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-publhealth-032315-021402","article-title":"Mediation analysis: a practitioner's guide","volume":"37","author":"VanderWeele","year":"2016","journal-title":"Annu Rev Public Health."},{"key":"10.1016\/j.ard.2026.07.005_bib0012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161908","article-title":"Clinical features of idiopathic interstitial pneumonia with systemic sclerosis-related autoantibody in comparison with interstitial pneumonia with systemic sclerosis","volume":"11","author":"Yamakawa","year":"2016","journal-title":"PLoS One."},{"key":"10.1016\/j.ard.2026.07.005_bib0013","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3899\/jrheum.170518","article-title":"KL-6 but not CCL-18 is a predictor of early progression in systemic sclerosis-related interstitial lung disease","volume":"45","author":"Salazar","year":"2018","journal-title":"J Rheumatol."},{"key":"10.1016\/j.ard.2026.07.005_bib0014","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1002\/art.41020","article-title":"Progression of interstitial lung disease in systemic sclerosis: the importance of pneumoproteins Krebs von den Lungen 6 and CCL18","volume":"71","author":"Volkmann","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.ard.2026.07.005_bib0015","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/resp.13988","article-title":"Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression","volume":"26","author":"Stock","year":"2021","journal-title":"Respirology."},{"key":"10.1016\/j.ard.2026.07.005_bib0016","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/rheumatology\/kead332","article-title":"Performance of serum biomarkers reflective of different pathogenic processes in systemic sclerosis-associated interstitial lung disease","volume":"63","author":"Gy\u00f6rfi","year":"2024","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.ard.2026.07.005_bib0017","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/acr.25485","article-title":"Treatment response biomarkers for systemic sclerosis-associated interstitial lung disease","volume":"77","author":"Volkmann","year":"2025","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"10.1016\/j.ard.2026.07.005_bib0018","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/acr.21716","article-title":"Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group","volume":"64","author":"Muangchan","year":"2012","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"10.1016\/j.ard.2026.07.005_bib0019","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/acr.21968","article-title":"Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis?","volume":"65","author":"Liu","year":"2013","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"10.1016\/j.ard.2026.07.005_bib0020","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1177\/0300060518760955","article-title":"High acute phase protein levels correlate with pulmonary and skin involvement in patients with diffuse systemic sclerosis","volume":"46","author":"Lis-\u015awi\u0119ty","year":"2018","journal-title":"J Int Med Res."},{"key":"10.1016\/j.ard.2026.07.005_bib0021","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1093\/rheumatology\/kead234","article-title":"Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease in a clinical trial and long-term observational cohort","volume":"63","author":"Ghuman","year":"2024","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.ard.2026.07.005_bib0022","first-page":"00558","article-title":"Effects of nintedanib on circulating biomarkers of idiopathic pulmonary fibrosis","volume":"10","author":"Jenkins","year":"2024","journal-title":"ERS Open Res."},{"key":"10.1016\/j.ard.2026.07.005_bib0023","doi-asserted-by":"crossref","first-page":"00158","DOI":"10.1183\/23120541.00158-2025","article-title":"Circulating biomarkers in subjects with progressive pulmonary fibrosis: data from the INBUILD trial","volume":"12","author":"Maher","year":"2026","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.ard.2026.07.005_bib0024","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12931-018-0876-y","article-title":"Differential effects of nintedanib and pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis","volume":"19","author":"Lehmann","year":"2018","journal-title":"Respir Res."},{"key":"10.1016\/j.ard.2026.07.005_bib0025","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3899\/jrheum.2025-0532","article-title":"Association of type III and type VI collagen neoepitopes with disease severity in systemic sclerosis","volume":"53","author":"Ayla","year":"2026","journal-title":"J Rheumatol."},{"key":"10.1016\/j.ard.2026.07.005_bib0026","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa1114576","article-title":"Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis","volume":"370","author":"van Bon","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ard.2026.07.005_bib0027","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s13075-016-1203-y","article-title":"Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease","volume":"18","author":"Volkmann","year":"2016","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.ard.2026.07.005_bib0028","doi-asserted-by":"crossref","first-page":"625","DOI":"10.21037\/tlcr.2017.09.13","article-title":"Ensuring sample quality for blood biomarker studies in clinical trials: a multicenter international study for plasma and serum sample preparation","volume":"6","author":"Kong","year":"2017","journal-title":"Transl Lung Cancer Res."},{"key":"10.1016\/j.ard.2026.07.005_bib0029","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1136\/ard-2022-222564","article-title":"Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON","volume":"81","author":"Allanore","year":"2022","journal-title":"Ann Rheum Dis."}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726004279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726004279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T01:47:43Z","timestamp":1786067263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726004279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":29,"alternative-id":["S0003496726004279"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.07.005","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating biomarkers in patients with systemic sclerosis\u2013associated interstitial lung disease in the SENSCIS trial","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}